If you suffered losses in Eagle Pharmaceuticals stock, contact Eagle Pharmaceuticals stock loss lawyer Timothy L. Miles
INTRODUCTION TO THE EAGLE PHARMACEUTICALS CLASS ACTION LAWSUIT![]()
The Eagle Pharmaceuticals class action lawsuit seeks to represent purchasers or acquirers of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) securities between August 8, 2023 and November 28, 2023, inclusive (the “Class Period”). Captioned Miller v. Eagle Pharmaceuticals, Inc., No. 23-cv-23011 (D.N.J.), the Eagle Pharmaceuticals class action lawsuit charges Eagle Pharmaceuticals and certain of its top current and former executive officers with violations of the Securities Exchange Act of 1934.
If you suffered losses in Eagle Pharmaceuticals stock and wish to serve as lead plaintiff in the Eagle Pharmaceuticals class action lawsuit, or just have general questions about your rights as a shareholder, please contact Eagle Pharmaceuticals Stock Loss Lawyer Timothy L. Miles at no charge by calling 855/846-6529 or via e-mail at [email protected] or by submitting a contact form. Lead plaintiff motions for the Eagle Pharmaceuticals class action lawsuit class action lawsuit must be filed with the court no later than February 9, 2024. Read on for answers to six frequently asked questions by investors about the Eagle Pharmaceuticals class action lawsuit. what are the ALLEGATIONS IN THE EAGLE PHARMACEUTICALS CLASS ACTION LAWSUIT?
Eagle Pharmaceuticals has several commercialized products, including PEMFEXY, which is a metabolic inhibitor used in combination with chemotherapy for the initial treatment of certain genomic tumor aberrations.
The Eagle Pharmaceuticals class action lawsuit alleges that, throughout the Class Period, defendants failed to disclose that: (i) Eagle Pharmaceuticals was experiencing slower than anticipated pull-though from a wholesale customer predominantly due to expiry of inventory; (ii) as a result, Eagle Pharmaceuticals had overstated its revenue; and (iii) Eagle Pharmaceuticals did not have effective internal controls and procedures over financial reporting as to PEMFEXY sales. The Eagle Pharmaceuticals class action lawsuit alleges that on November 9, 2023 Eagle Pharmaceuticals announced that it would not release its third quarter 2023 results that day (as had been expected) because Eagle Pharmaceuticals “requires more time to review potential adjustments relating to the reporting of sales of PEMFEXY® prior to filing its Form 10-Q” and that Eagle Pharmaceuticals “expects to revise its previously disclosed 2023 full year guidance downward.” On this news, Eagle Pharmaceuticals’ stock price more than 30%, according to the complaint. The Eagle Pharmaceuticals class action lawsuit further alleges that later on November 9, 2023 after the market closed, Eagle Pharmaceuticals disclosed that it was reviewing “potential adjustments to reserves for returns and price adjustments of approximately $15.0 million to $20.0 million” related “to returns and a price adjustment for PEMFEXY stemming from slower-than-anticipated pull-through from a wholesale customer predominantly due to expiry of inventory.” On this news, Eagle Pharmaceuticals’ stock price fell nearly 3%, the complaint alleges. Then, on November 29, 2023, the Eagle Pharmaceuticals class action lawsuit also alleges that Eagle Pharmaceuticals disclosed that its President and CEO, defendant Scott Tarriff, resigned and that Eagle Pharmaceuticals’ board of directors accepted the resignation “[a]fter consideration of various alternatives, including termination with or without cause.” On this news, Eagle Pharmaceuticals’ stock price fell an additional 31%, the complaint alleges. WHAT ARE MY CHOICES IF I RECEIVE A NOTICE IN THE EAGLE PHARMACEUTICALS CLASS ACTION LAWSUIT?
First, read the notice very carefully. You have two choices. First, you can do nothing and remain a member of the class represented by lead counsel. Second, if you believe you have a large enough loss to justify it, you can opt out of the Eagle Pharmaceuticals class action lawsuit and file your own separate lawsuit. Note, that if you opt out, you will not be able to participate in any settlement or recovery obtained in the Eagle Pharmaceuticals class action lawsuit.
WHAT IS A SECURTIES FRAUD CLASS ACTION SUCH AS THE EAGLE PHARMACEUTICALS CLASS ACTION LAWSUIT?
A securities fraud class action refers to a legal action taken by a group of investors who have suffered financial losses as a result of fraudulent activities committed by a company or its executives. This type of lawsuit is typically filed when a company misrepresents or withholds important information from investors, leading to a decline in the value of their investments. The purpose of a securities fraud class action is to seek compensation for the affected investors and hold the company accountable for its fraudulent practices. Securities fraud class actions are governed by the Private Securities Litigation Reform Act (PSLRA).
One notable securities fraud class action lawsuit is the Eagle Pharmaceuticals class action lawsuit. In this case, investors who purchased Eagle Pharmaceuticals securities alleged that the company made false and misleading statements and misled investors, and when the truth was ultimately disclosed, they suffered losses from purchasing shares that had been artificially inflated by the false and misleading information. Securities fraud class actions are typically initiated by a lead plaintiff or a group of lead plaintiffs who represent the interests of all the affected investors. The lead plaintiff is often an institutional investor or a large shareholder who has suffered substantial losses and possesses the resources and expertise to effectively pursue the lawsuit on behalf of the class. The lead plaintiff's role is crucial in coordinating with legal counsel, gathering evidence, and making strategic decisions throughout the litigation process. To proceed with a securities fraud class action, the lead plaintiff must demonstrate that there is a common issue of law or fact among the members of the class and that a class action is the most efficient and appropriate method for resolving their claims. If these requirements are met, the court will certify the lawsuit as a class action, allowing all eligible investors to participate in the litigation and share in any potential recovery. Once certified, the securities fraud class action typically goes through several stages, including discovery, where both parties exchange relevant documents and information, and motion practice, where each side presents legal arguments to the court. If the case does not settle during these stages, it may proceed to trial, where a jury or judge will determine liability and damages. In securities fraud class actions, the defendants are usually the company accused of fraud and its executives who were involved in the fraudulent activities. The lead plaintiff seeks damages on behalf of all class members, which may include compensation for their financial losses, interest, attorneys' fees, and other costs incurred throughout the litigation process. In conclusion, a securities fraud class action is a legal mechanism used by investors to seek compensation for financial losses resulting from fraudulent activities committed by a company. The Eagle Pharmaceuticals class action lawsuit serves as an example of how investors can hold companies accountable for their alleged misrepresentations and omissions. These lawsuits play an essential role in protecting investor rights and promoting transparency in the financial markets. CAN A NON-U.S. INVESTOR SERVE AS LEAD PLAINTIFF IN THE EAGLE PHARMACEUTICALS LAWSUIT?
Yes, courts in the U.S. have consistently recognized that non-U.S. investors, many of whom have substantial holdings, are adequate lead plaintiffs and have the same right to move for lead plaintiffs as U.S. investors. Thus, if a non-U.S. investor suffered losses in Eagle Pharmaceuticals stock, they may move the Court to be appointed lead plaintiff in the Eagle Pharmaceuticals lawsuit.
WHAT ARE THE BENEFITS OF SERVING AS LEAD PLAINTIFF IN THE EAGLE PHARMACEUTICALS LAWSUIT?
Serving as a Lead Plaintiff in the Eagle Pharmaceuticals lawsuit has several advantages and important benefits including:
Thus, there are numerous benefits and other advantages to serving as lead plaintiff in a class action against Eagle Pharmaceuticals if you suffered significant losses in Eagle Pharmaceuticals stock. HOW WAS THE CLASS PERIOD DETERMINED IN THE EAGLE PHARMACEUTICALS LAWSUIT?
In a securities fraud class action, the class period refers to a period of time in which it is alleged the price of the company’s stock was artificially inflated due to false and misleading statements made by company executives. The class period starts when the company makes an untrue statement of material fact about the company or fails to disclose a material fact necessary to render other statements not misleading. The class period ends when the truth is revealed to the investing public through a corrective disclosure.
To be a part of the class in the Eagle Pharmaceuticals lawsuit, you must have suffered losses in Eagle Pharmaceuticals stock by purchasing during the class period when it is alleged the price of the stock was artificially inflated to be included in the class action against Eagle Pharmaceuticals. CONTACT AN EAGLE PHARMACEUTICALS STOCK LOSS LAWYER TODAY IF YOU SUFFERED LOSSES IN EAGLE PHARMACEUTICALS STOCK ABOUT A EAGLE PHARMACEUTICALS CLASS ACTION LAWSUIT
If you suffered losses in Eagle Pharmaceuticals stock, contact Eagle Pharmaceuticals stock loss lawyer Timothy L. Miles today for a free case evaluation about an Eagle Pharmaceuticals class action lawsuit. Call today and see what an Eagle Pharmaceuticals stock loss lawyer could do for you if you suffered losses in Eagle Pharmaceuticals stock.
The Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center 300 Centerview Dr., #247 Brentwood, TN 37027 Phone: (855) 846–6529 Email: [email protected] Eagle Pharmaceuticals stock loss lawyer Timothy L. MilesNashville attorney Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles has dedicated his career to representing shareholders, employees, and consumers in complex class-action litigation. Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for defrauded investors, shaped precedent-setting decisions, and delivered real corporate governance reforms. Judges and peers have repeatedly recognized Mr. Miles’ relentless advocacy for the underdog, as well as his unbendable ethical standards. Mr. Miles was recently selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association,Class Action: Class Action: Top National Trial Lawyers, National Trial Lawyers Association (2023), a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019); a Top Rated Litigator by Martindale-Hubbell® and ALM (2019-2022); America’s Most Honored Lawyers 2020 – Top 1% by America’s Most Honored (2020-2022). Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, civil procedure, derivative actions, corporate takeover litigation, corporate formation, mass torts, dangerous drugs, and more. Please visit our website or call for free anytime. Comments are closed.
|
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
July 2024
Categories
All
|
CONTACT
The Law Offices of Timothy L. Miles Tapestry at Brentwood Town Center 300 Centerview Dr., #247 Brentwood, TN 37027 Phone: (855) 846-6529 Email: [email protected] HOURS OF OPERATION Mon-Fri: 24/7 Sat-Sun: 24/7 |